Professor Tom Vanden Berghe earned his Master's and PhD in Science (Biotechnology) in 1999 and 2005, respectively. Following his doctoral studies, he pursued postdoctoral research at the VIB-UGent Center for Inflammation Research. In 2018, he was appointed as an Assistant Professor at the University of Antwerp and as a Guest Professor at Ghent University. In 2023, he was promoted to an Associate Professor.
Professor Vanden Berghe is head of the Cell Death Signaling Lab at University of Antwerp. His mission is to conduct applied research focusing on cell death, particularly ferroptosis, pyroptosis (inflammation), and associated diseases. The Vanden Berghe Lab investigates mechanisms, diagnostics, and intervention strategies related to critical illnesses, brain injuries, kidney and vascular diseases. In addition, the team explores the potential of ferroptosis as a novel anti-cancer therapy for eliminating therapy-resistant cancers. Professor Vanden Berghe has established a comprehensive ferroptosis platform encompassing novel lead ferroptosis inhibitors and genes, ferroptosis diagnostics, and ferroptosis-based nanomedicine for anti-cancer therapeutics.
Title | Cited by |
2024
Improving cardiac differentiation of human pluripotent stem cells by targeting ferroptosis
Regenerative therapy 27, 21-31, 2024
|
0
|
2024
Emerging role of ferroptosis in metabolic dysfunction-associated steatotic liver disease: revisiting hepatic lipid peroxidation
EBioMedicine 102, 2024
|
0
|
2024
Reducing reagent-resistant transferrin receptor 1 dimer is a specific marker for ferroptosis
Cancer Research 84 (6_Supplement), 357-357, 2024
|
0
|
2024
Loss of PPARα function promotes epigenetic dysregulation of lipid homeostasis driving ferroptosis and pyroptosis lipotoxicity in metabolic dysfunction associated Steatotic …
Frontiers in Molecular Medicine 3, 1283170, 2024
|
0
|
2023
Beyond ferrostatin-1: a comprehensive review of ferroptosis inhibitors
Trends in Pharmacological Sciences, 2023
|
10
|
2023
A Guide to Ferroptosis, the biological rust of cellular membranes
The FEBS Journal, 2023
|
1
|
2023
Effect of erythrophagocytosis-induced ferroptosis during angiogenesis in atherosclerotic plaques
Angiogenesis 26 (4), 505-522, 2023
|
8
|
2023
Ferroptosis and pyroptosis signatures in critical COVID-19 patients
Cell Death & Differentiation 30 (9), 2066-2077, 2023
|
5
|
2023
Ferroptosis contributes to multiple sclerosis and its pharmacological targeting suppresses experimental disease progression
Cell Death & Differentiation 30 (9), 2092-2103, 2023
|
7
|
2023
Zonated quantification of immunohistochemistry in normal and steatotic livers
Virchows Archiv 482 (6), 1035-1045, 2023
|
3
|
2023
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Cell Death & Differentiation 30 (5), 1097-1154, 2023
|
77
|
2023
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD
European Respiratory Journal 61 (4), 2023
|
15
|
2023
Molecular mechanisms of nemorosone-induced ferroptosis in cancer cells
Cells 12 (5), 735, 2023
|
5
|
2023
Caspase inhibition modulates monocyte-derived macrophage polarization in damaged tissues
International Journal of Molecular Sciences 24 (4), 4151, 2023
|
1
|
2022
Zonated quantification of immunohistochemistry in steatotic livers
Journal of Hepatology 77, S709, 2022
|
0
|
2022
Correction to: Luminescent Human iPSC-Derived Neurospheroids Enable Modeling of Neurotoxicity After Oxygen–glucose Deprivation
Neurotherapeutics 19 (4), 1433, 2022
|
0
|
2022
Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity
Nature communications 13 (1), 3676, 2022
|
125
|
2022
Novel iron oxide nanoparticles induce ferroptosis in a panel of cancer cell lines
Molecules 27 (13), 3970, 2022
|
29
|
2022
Inhibiting RIPK1 kinase activity is protective in experimental models of COPD
ERJ Open Research 8 (suppl 8), 2022
|
2
|
2022
Luminescent human iPSC-derived neurospheroids enable modeling of neurotoxicity after oxygen–glucose deprivation
Neurotherapeutics 19 (2), 550-569, 2022
|
9
|
Number | Name | Date |
US9862678, WO2016075330, EP3218357 | 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death | 2014-11-14 |
WO2019154795, EP3749645, CN112105601, US20210094909, 201980012162.8 | 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. stroke | 2018-02-07 |
WO2015110346, US9919048 | Targeting of interleukin-1 and -18 signaling in treatment of septic shock | 2014-01-21 |
EP22196811 | New Ferroptosis Inhibitors | 2022-09-21 |